Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies 
Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
NRW Holdings Shares Surge After Securing Major Rio Tinto Contract and New Project Wins 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
Qantas to Sell Jetstar Japan Stake as It Refocuses on Core Australian Operations 
Denso Cuts Profit Forecast Amid U.S. Tariffs and Rising Costs 
Sam Altman Reaffirms OpenAI’s Long-Term Commitment to NVIDIA Amid Chip Report 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Elon Musk’s SpaceX Acquires xAI in Historic Deal Uniting Space and Artificial Intelligence 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock 
PALO ALTO, Calif., Aug. 09, 2017 -- Medable Inc., the leading application and analytics platform for healthcare, today announced Tyler Pugsley has joined the company as Vice President of Life Sciences. Pugsley was the Director of Business Development for IBM Watson Health.
|
|||||
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/64618bed-5bf5-4b24-b4e0-3961496ec3b8
“Medable is leading a new era in clinical research, in which technology enables clinical trials to be taken directly to patients, anytime, anywhere,” said Dr. Michelle Longmire, Medable CEO. “We are excited that Tyler has joined us in our mission to transform the life sciences industry. With our technology and Tyler’s industry experience, we will usher in a new era marked by globally scaled trial participation and better and more true to life data.”
Pugsley comes with a strong understanding of clinical trials and healthcare analytics, having spent the last two years with IBM Watson where he was instrumental in acquiring new pharma, biotech and Contract Resource Organization (CRO) partners.
“Medable has a truly innovative team and technology which is set to disrupt the $30 billion clinical trial outsourcing market,” said Pugsley. “For years the clinical trials industry has been saddled by legacy technology and workflow inefficiencies.
“Medable’s industry leading platform puts patients first and enables innovation at all levels of clinical trials allowing more efficient real world data collection, monitoring and analysis,” said Pugsley. “As a team, we are passionate about bringing greater value to patients and more effective therapeutics to market.”
ABOUT MEDABLE
Privately-held Palo Alto, California-based Medable provides a comprehensive, secure HIPAA-compliant cloud-based platform purpose-built for healthcare. Medable’s Axon is a “no coding required” solution enabling researchers to deliver smartphone clinical studies on a secure, HIPAA compliant technology stack. Medable’s Synapse is a clinical care app solution for providers and patients. Medable’s Cortex is the fastest way for developers to create scalable, EHR interoperable, HIPAA compliant applications. Medable’s Cerebrum is the first cloud-based machine learning solution created specifically for healthcare apps. For more information visit: www.medable.com
Follow Medable on Twitter: @Medablelinc
The photo is also available via AP PhotoExpress.
Gary Poole, PR Director [email protected]
